Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Guidances Could Be Left Out In Cold By White House Regulatory Freeze

Executive Summary

Trump Administration memo could further delay some US FDA guidance documents already past due under the FDA Safety and Innovation Act; attorneys predict uncertainty about, but no immediate impact on, biosimilar and communications draft guidances released in last few weeks of the Obama Administration.

You may also be interested in...



FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival

Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.

Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.

Off-Label Communication: When Does It Align With Approved Labeling?

US FDA draft guidance offers three-factor test to determine when communication about a medical product is consistent with labeling; information on patient-reported outcomes and mechanism of action are okay.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB002217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel